GLP-1 Titration Calculator — Semaglutide & Tirzepatide Dose Schedule

Last updated: June 2026

About the GLP-1 Titration Planner

The GLP-1 Titration Planner builds a week-by-week dose escalation schedule for GLP-1 medications such as semaglutide, tirzepatide and retatrutide. Instead of guessing how a ramp from a starting dose up to a target dose plays out, you pick the medication, set your start and target dose, choose how fast you want to escalate, and enter your vial concentration and vial size. The planner then lays out every step: the week range, the dose in mg, the U-100 syringe units and the draw volume in mL — plus the total mg used through the whole titration, how many vials that takes and the monthly mg once you reach target. Free, no login.

It is built for anyone ramping a GLP-1 who wants to see the whole escalation schedule in one place — the dose at each step, the units to draw each week, and how many vials the full ramp will get through — rather than working it out one week at a time.

How to use it

Pick your medication — semaglutide, tirzepatide or retatrutide — then set your start dose and your target dose in mg. The standard ladders are loaded so the steps between start and target follow the recognised dose increments for each compound.

Choose an escalation pace: slow (8 weeks per step), standard (4 weeks per step) or aggressive (2 weeks per step). Then enter the vial concentration in mg/mL and the vial size in mg. As soon as the fields are filled, the planner shows the full week-by-week table and the totals — there is no calculate button to press.

Remember the pace is a planning input, not a clinical instruction: you only step up once the side effects of your current dose have settled.

Worked example

Semaglutide — standard pace (4 weeks per step)

Weeks 1–4: 0.25 mg weekly

Weeks 5–8: 0.5 mg weekly

Weeks 9–12: 1.0 mg weekly

Weeks 13–16: 1.7 mg weekly

Week 17 onward: 2.4 mg weekly (maintenance)

Units at the 2.4 mg target (2.4 mg/mL vial)

Draw volume = 2.4 / 2.4 = 1.0 mL

U-100 units = (2.4 / 2.4) × 100 = 100 units

2.4 mg = 1.0 mL = 100 units

The math behind it

The GLP-1 Titration Planner is built on a few plain relationships:

Each escalation step lasts (pace) weeks — 8 weeks for slow, 4 for standard, 2 for aggressive — so the week range for a step is the running week count across the ladder.
U-100 syringe units = (dose in mg / concentration in mg/mL) × 100
Draw volume (mL) = dose in mg / concentration in mg/mL
Vials needed = roundup(total titration mg / vial mg), where total titration mg is the sum of every weekly dose across the whole schedule.

Each step's dose comes from the standard ladder for the chosen medication; the units and draw volume are recalculated for every step from your vial's concentration, and the vial count is driven by the total milligrams the full ramp gets through.

Standard escalation schedules

The planner loads these recognised weekly ladders:

Semaglutide: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly
Tirzepatide: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly
Retatrutide (investigational): example phase-2 trial doses such as 1 → 2 → 4 → 8 → 12 mg weekly. Retatrutide is not FDA-approved and these figures come from study arms, not an approved label.

Frequently asked questions

How fast should I escalate a GLP-1 dose?

Standard manufacturer labelling steps up roughly every 4 weeks, but the right pace is driven by tolerability, not the calendar. A slower pace (around 8 weeks per step) is common for people who get strong nausea, while a faster pace is only appropriate under prescriber supervision. The planner lets you model slow (8 weeks/step), standard (4 weeks/step) or aggressive (2 weeks/step) so you can see the schedule, but you should only step up once side effects from the current dose have settled.

How are the syringe units worked out?

On a U-100 insulin syringe, units = (dose in mg / vial concentration in mg/mL) × 100, and the draw volume in mL = dose / concentration. For 2.4 mg of semaglutide from a 2.4 mg/mL vial that is 2.4 / 2.4 = 1.0 mL = 100 units.

Why is retatrutide marked as investigational?

Retatrutide is an experimental triple agonist still in clinical trials and is not approved by the FDA or any major regulator for any use. The doses shown for it (for example 1, 2, 4, 8 and 12 mg) are taken from published phase-2 study arms, not from an approved label. It is included for reference only and is not a recommendation to use it.

What should I do if I get nausea?

Nausea is the most common GLP-1 side effect and usually eases as your body adjusts to a given dose. The standard approach is to hold the current step longer rather than escalate, and to only move up once symptoms have settled. Severe or persistent nausea, vomiting or dehydration should be discussed with your prescriber, who may slow the titration or hold the dose.

Other calculators

Semaglutide Dosage Calculator Tirzepatide Dosage Calculator Retatrutide Dosage Calculator Reverse Dose Solver

Related guides

How this is calculated

This planner spreads the standard dose ladder for your chosen medication across the weeks at your selected pace, then for each step divides the dose (mg) by your vial concentration (mg/mL) to give the draw volume in mL and multiplies by 100 for U-100 syringe units. It sums every weekly dose for the total titration mg and rounds up against your vial size for the vial count. It is unit-conversion and scheduling arithmetic only — nothing is stored — and it is not medical advice. GLP-1 titration must be individualised and supervised by a prescriber and is driven by tolerability: step up only once side effects from the current dose have settled. Retatrutide is investigational and not approved for use. Always confirm your medication, schedule and vial concentration with your prescriber.